Emily Hague, Imaging Performance Partnership
A recent study, published in this month’s Radiology, examined the effectiveness of PET/MR in staging lung cancer, compared with more commonly used PET/CT.
The researchers, from Eberhard-Karls University in Tübingen, Germany, found that PET/MR produced diagnostic-quality images and concluded PET/MR has potential to replace PET/CT as the modality of choice—resulting in a 75% reduction radiation exposure.
PET/MR: As good as PET/CT without the risk?
In a somewhat surprising move in light of the many changes underway with health care reform legislation, the Centers for Medicare and Medicaid Services (CMS) has further expanded its National Coverage Determination policy for FDG-PET imaging of solid tumors and myelomas. The recent move grants more opportunity for providers of PET imaging services to receive reimbursement when FDG-PET is used to inform the initial treatment plans for cancer patients. The policy revision marks the second time in the past year in which CMS has expanded coverage for FDG-PET imaging of tumors. While this move will be welcomed by many patients and providers alike, it may be a ripe proving ground for CMS at the national and local levels to engage in further utilization review for advanced imaging services.
CMS to Lift "Only One" Provision from PET Coverage Policy
From 2008 to 2009, respondents overall exhibited strong growth in PET volumes (I'm referring to PET volumes that are performed on either PET scanners or hybrid PET/CT scanners).
Volume Trends Survey: PET and PET-CT